Analytiker: Novos nye diabetesprodukt er en gamechanger

”Det her vil være gamechanging for Novo Nordisk over de næste ti år, for det her produkt er markant bedre end andre på markedet,” siger Claus henrik Johansen, senior porteføljeforvalter i Danske Capital.

Semaglutide er Novos nye diabetesprodukt, og…

You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

You must be logged in to post a comment.

Powered by WordPress | Designed by: Premium Themes | Thanks to Free WordPress 4 Themes, Download Premium WordPress Themes and
%d bloggers like this: